Understanding mechanisms of impaired immunity in the AML bone marrow
Description: PROJECT NARRATIVE Immune-based therapies have transformed the treatment of many hematologic malignancies, but such approaches have had limited success for acute myeloid leukemia (AML), an aggressive hematologic malignancy that remains fatal in nearly half of diagnosed cases. However, there is great potential for T cell- based immunotherapeutic approaches for treating AML given (1) studies demonstrating impaired T cell immunity in AML patients, (2) clinical data illustrating correlation between the bone marrow immune landscape and treatment responses to both chemotherapy and immunotherapy, and (3) the curative potential of allogeneic hematopoietic cell transplantation for AML arising from the immune-mediated graft-versus-leukemia activity of donor T cells. The goal of this study is to perform deep analysis of T cells in parallel with surrounding populations in the bone marrow, the site where AML emerges, to elucidate key mechanisms driving T cell functional responses to AML longitudinally, and to identify immunologic targets for potential therapeutic intervention.
Funder: National Cancer Institute
Funding type: career_development
Funder scheme: K08
Start date: 2024-07-01
End date: 2029-06-30
Investigator: SUSAN E DEWOLF
Institution: SLOAN-KETTERING INST CAN RESEARCH
Funded outputs count: 11
Funder award ID: K08CA293271
OpenAlex ID: G9000881768